Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products

Costache, Irina‐Iuliana; Hăncianu, Monica; Aursulesei, Viviana; Costache, Alexandru Dan; Aprotosoaie, Ana Clara

doi:10.1155/2019/9402781

Cited by 14 publications

(7 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The phytochemistry of S. flavescens and S. japonicum are different with the flavone glucosides of luteolin 7‐ O ‐glucoside and apigenin 7‐ O ‐glucoside being abundant in the flower and bud of S. flavescens but absent in S. japonicum (Kite et al, 2009); therefore, these plants can easily be distinguished by HPLC. Because S. japonicum flower and flower bud are rich in flavonol glycosides, extracts from these ingredients have been used to adulterate Ginkgo biloba leaf extracts (Avula et al, 2015; Costache et al, 2019). Adulteration with S. japonicum flower extract results in a higher concentration of flavonol glycosides (up to 24%), which is similar to the specifications for most Ginkgo extract products (Gafner, 2018).…”

Section: Pharmacopeial Qualitymentioning

confidence: 99%

United States Pharmacopeia comprehensive safety review of Styphnolobium japonicum flower and flower bud

Madden

McLachlan

Oketch-Rabah

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

The dried flower and flower bud of Styphnolobium japonicum (L.) Schott (Japanese Sophora flower and Japanese Sophora flower bud, respectively) have long been used as herbal medicines in Asia. Today, they are marketed as dietary supplements in the United States for their anti‐oxidative properties and as a source of flavonoids, including rutin and quercetin. This review focused on the safety of S. japonicum flower and flower bud as dietary supplement ingredients. No serious adverse events or toxicity were reported in the clinical or experimental animal studies we reviewed. Although some studies indicated that rutin or quercetin may have potential for drug interactions, none were identified for S. japonicum flower or flower bud. S. japonicum flower and flower bud are not known to have been associated with serious health risks when appropriately consumed in dietary supplements and have been admitted to the U.S. Pharmacopeial Convention monograph development process. However, pregnant and breastfeeding women should seek the advice of a healthcare professional because no data are available on their use by these special populations.

show abstract

Section: Pharmacopeial Qualitymentioning

confidence: 99%

United States Pharmacopeia comprehensive safety review of Styphnolobium japonicum flower and flower bud

Madden

McLachlan

Oketch-Rabah

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Information on herbs-herbal products/ drug/component interactions is based on in vitro tests, in vivo animal experiments, Figure 1. The important risk factors that influence the occurrence of interactions between herbal products and conventional drugs [13].…”

Section: Herb-drug Interactions (Hdi)mentioning

confidence: 99%

The Clinical Importance of Herb-Drug Interactions and Toxicological Risks of Plants and Herbal Products

Kahraman¹,

Arıtuluk²,

Cankaya³

2021

Medical Toxicology

View full text Add to dashboard Cite

Approximately 70% of the world's population has been using medicinal herbs as a complementary or alternative medicine that has grown tremendously in both developed and developing countries over the past 20 years (World Health Organization Drugs Strategy 2002-2005). This increase in consumer demand for medicinal plants continues, although scientific data are rare to create safety and efficacy profiles. Its popularity is also related to easy availability, cost-effectiveness leading to better purchasing power, and various factors that perceive that they are generally safe. Herbs are often administered simultaneously with therapeutic drugs for the treatment of major ailments, and herb-drug interactions (HDIs) increase their potential. The main routes proposed for HDIs include cytochrome P450 (CYP450)-mediated inhibition or induction and transport and flow proteins. In our review, we highlighted herbal medicines used for the treatment of various diseases with pharmacokinetic, pharmacodynamic analysis and case reports together with their adverse effects and herb-drug interactions. Therefore, this review can be used as a quick reference database for physicians and healthcare professionals involved in therapy, aiming to maximize clinical outcomes by reducing the negative and toxic effects of plants along with avoiding herb-drug interactions.

show abstract

“…Vitamin A (all-trans-retinol) is a provitamin found in vegetables that exists in different metabolic states: retinal (retinaldehyde), oxidized forms and conjugations of retinol and retinoic acid. The term retinoid was introduced in 1970 and gathers under its name all chemical compounds that structurally resemble all-trans-retinol, with all its metabolites, both natural and synthetic [120,121].…”

Section: Vitamin Amentioning

confidence: 99%

The Effect of Vitamin Supplementation on Subclinical Atherosclerosis in Patients without Manifest Cardiovascular Diseases: Never-ending Hope or Underestimated Effect?

et al. 2020

Self Cite

View full text Add to dashboard Cite

Micronutrients, especially vitamins, play an important role in the evolution of cardiovascular diseases (CVD). It has been speculated that additional intake of vitamins may reduce the CVD burden by acting on the inflammatory and oxidative response starting from early stages of atherosclerosis, when the vascular impairment might still be reversible or, at least, slowed down. The current review assesses the role of major vitamins on subclinical atherosclerosis process and the potential clinical implications in patients without CVD. We have comprehensively examined the literature data for the major vitamins: A, B group, C, D, and E, respectively. Most data are based on vitamin E, D and C supplementation, while vitamins A and B have been scarcely examined for the subclinical atherosclerosis action. Though the fundamental premise was optimistic, the up-to-date trials with vitamin supplementation revealed divergent results on subclinical atherosclerosis improvement, both in healthy subjects and patients with CVD, while the long-term effect seems minimal. Thus, there are no conclusive data on the prevention and progression of atherosclerosis based on vitamin supplementation. However, given their enormous potential, future trials are certainly needed for a more tailored CVD prevention focusing on early stages as subclinical atherosclerosis.

show abstract

Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products

Cited by 14 publications

References 104 publications

United States Pharmacopeia comprehensive safety review of Styphnolobium japonicum flower and flower bud

United States Pharmacopeia comprehensive safety review of Styphnolobium japonicum flower and flower bud

The Clinical Importance of Herb-Drug Interactions and Toxicological Risks of Plants and Herbal Products

The Effect of Vitamin Supplementation on Subclinical Atherosclerosis in Patients without Manifest Cardiovascular Diseases: Never-ending Hope or Underestimated Effect?

Contact Info

Product

Resources

About